Perioperative nivolumab not only extends event-free survival (EFS) but also does not compromise quality of life in patients with resectable non-small cell lung cancer (NSCLC), including those with ...
This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results